Medically reviewed by Marla Anderson, MD HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is ...

"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically ...

The following is a summary of "HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials ...

The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...

Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III ...

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

The FDA has granted priority review to the new drug application for zongertinib to treat adults with unresectable or metastatic, HER2-mutant NSCLC who have received prior systemic therapy.

CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining ...